SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	6,210,241	9,757,831	8,700,602	7,862,650	5,646,385	7,612,048
Market Cap Growth	-12.86%	12.15%	10.66%	39.25%	-25.82%	-42.48%
Enterprise Value	5,949,361	9,567,696	8,637,734	7,807,605	5,442,304	7,267,516
Last Close Price	79300.00	124600.00	111100.00	100400.00	72100.00	97200.00
PE Ratio	17.81	36.55	36.14	-	-	117.39
Forward PE	19.08	39.32	73.81	-	-	-
PS Ratio	7.86	13.81	15.89	22.16	22.94	18.18
PB Ratio	6.66	11.81	15.16	24.50	17.84	17.14
P/TBV Ratio	7.08	12.11	16.24	29.59	18.86	17.90
P/FCF Ratio	39.11	57.59	93.05	-	-	-
P/OCF Ratio	37.19	55.34	91.68	-	-	-
PEG Ratio	0.96	4.68	-	-	-	-
EV/Sales Ratio	7.53	13.54	15.77	22.00	22.11	17.36
EV/EBITDA Ratio	23.65	43.32	75.93	-	-	68.18
EV/EBIT Ratio	25.29	46.92	89.66	-	-	76.53
EV/FCF Ratio	37.47	56.47	92.38	-	-	-
Debt / Equity Ratio	0.05	0.06	0.32	0.56	0.49	0.04
Debt / EBITDA Ratio	0.18	0.22	1.62	-	-	0.15
Debt / FCF Ratio	0.32	0.29	1.97	-	-	-
Net Debt / Equity Ratio	-0.28	-0.31	-0.24	-0.20	-0.47	-0.72
Net Debt / EBITDA Ratio	-0.92	-1.18	-1.23	2.84	1.27	-2.99
Net Debt / FCF Ratio	-1.64	-1.54	-1.50	0.65	0.91	3.28
Asset Turnover	0.68	0.63	0.62	0.51	0.38	0.73
Inventory Turnover	0.45	0.41	0.40	0.35	0.53	0.60
Quick Ratio	1.94	1.83	1.26	1.47	2.28	2.64
Current Ratio	2.49	2.31	1.64	2.02	2.99	3.18
Return on Equity (ROE)	44.16%	36.17%	50.72%	-11.10%	-36.66%	15.75%
Return on Assets (ROA)	14.43%	11.40%	6.84%	-3.38%	-12.53%	10.38%
Return on Invested Capital (ROIC)	43.34%	40.80%	27.85%	-17.66%	-89.60%	127.86%
Return on Capital Employed (ROCE)	26.60%	22.60%	15.00%	-7.80%	-26.20%	19.20%
Earnings Yield	5.62%	2.74%	2.77%	-0.42%	-2.47%	0.85%
FCF Yield	2.56%	1.74%	1.07%	-1.23%	-2.92%	-1.28%
Buyback Yield / Dilution	-0.07%	-	-	-	-	-9.12%